Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition. Click here to ...

If approved, garadicimab will slot into CSL's product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks ...

If approved, garadicimab will slot into CSL’s product line alongside two C1 esterase inhibitor medicines, namely Berinert, which is administered by intravenous injection to treat HAE attacks ...

CSL Behring, of King of Prussia, Pennsylvania, gained CBER approval in the same indication, for Berinert, a plasma-derived version of C1 esterase inhibitor. In mainstream indications, however ...

In 2025, seniors will pay less for 64 medications if they get them through Medicare Part B, which covers outpatient care, including drugs that are administered at a doctor’s office. The price ...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...

The complement system consists of more than 30 proteins that have long been known to participate to the immune defence against pathogens and to the removal of damaged cells. Their role, however, ...